Premium
Silica‐tethered cuprous acetophenone thiosemicarbazone (STCATSC) as a novel hybrid nano‐catalyst for highly efficient synthesis of new 1,2,3‐triazolyl‐based metronidazole hybrid analogues having potent antigiardial activity
Author(s) -
Soltani Rad Mohammad Navid,
Behrouz Somayeh,
MohammadtaghiNezhad Javad,
Zarenezhad Elham,
Agholi Mahmoud
Publication year - 2019
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.4799
Subject(s) - chemistry , thermogravimetric analysis , acetophenone , catalysis , nuclear chemistry , organic chemistry
The preparation, characterization and application of silica‐tethered cuprous acetophenone thiosemicarbazone (STCATSC) as a novel hybrid nano catalyst for synthesis of new 1,2,3‐triazolyl‐based metronidazole hybrid analogues is described. STCATSC is fully characterized by different microscopic, spectroscopic and physical techniques, including scanning electron microscopy (SEM), transmission, X‐ray diffraction (XRD), Energy‐dispersive X‐ray spectroscopy (EDS), thermogravimetric analysis (TGA), FT‐IR and inductively coupled plasma (ICP) analysis. This catalyst is used to prepare the new 1,2,3‐triazolyl‐based metronidazole hybrid analogues. The ‘Click’ Huisgen cycloaddition reaction of 2‐methyl‐5‐nitro‐1‐prop‐2‐ynyl‐1 H ‐imidazole with diverse β‐azidoalcohols in a THF‐water media at R.T. provides the products in good to excellent yields using STCATSC. STCATSC is proved to be a stable, low cost, reusable and environmentally benign hybrid catalyst. Products are in vitro tested against Giardia lamblia ( G. lamblia ) in which determined that all compounds exhibit varied promising antigiardial activity compare to metronidazole as a reference drug. Among the products, 1‐(4‐((2‐methyl‐5‐nitro‐1 H ‐imidazol‐1‐yl)methyl)‐1 H ‐1,2,3‐triazol‐1‐yl)‐3‐phenethoxypropan‐2‐ol and 1‐(4‐((2‐methyl‐5‐nitro‐1 H ‐imidazol‐1‐yl)methyl)‐1 H ‐1,2,3‐triazol‐1‐yl)‐3‐(3‐phenylpropoxy)propan‐2‐ol are demonstrated to exhibit the potent antigiardial activity even stronger than metronidazole.